1. Weinstock H, Berman S and Cates W, Jr., Sexually transmitted diseases among American youth: incidence and prevalence estimates, Perspectives on Sexual and Reproductive Health, 2004, 36(1):6-10.
2. Siegel JE, Estimates of the economic burden of STDs: review of the literature with updates, in: Eng TR and Butler WT, eds., The Hidden Epidemic: Confronting Sexually Transmitted Diseases, Washington, DC: National Academy Press, 1997, pp. 330-356; and American Social Health Association (ASHA), Sexually Transmitted Diseases in America: How Many Cases and at What Cost? Menlo Park, CA: Kaiser Family Foundation, 1998.
3. Cunningham WE et al., Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States, Journal of Acquired Immune Deficiency Syndromes, 2000, 25(2):115-123.
4. Seigel JE, 1997, op. cit. (see reference 2); and Haddix AC, Teutsch SM and Corso PS, eds., Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, New York: Oxford University Press, 2003.
5. Economic Report of the President: Transmitted to the Congress February 2002, Table B-60: Consumer price indexes for major expenditure classes, 1958-2001, p. 389, , accessed Sept. 10, 2003.
6. Corso PS and Haddix AC, Time effects, in: Haddix AC, Teutsch SM and Corso PS, 2003, op. cit. (see reference 4); and Gold MR et al., eds., Cost-Effectiveness in Health and Medicine, New York: Oxford University Press, 1996.
7. Corso PS and Haddix AC, 2003, op. cit. (see reference 6).
8. Weinstock H, Berman S and Cates W, Jr., 2004, op. cit. (see reference 1).
9. Holtgrave DR and Pinkerton SD, Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1997, 16(1):54-62.
10. Bozzette SA et al., Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy, New England Journal of Medicine, 2001, 344(11):817-823.
11. Walensky RP et al., Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy, Journal of Acquired Immune Deficiency Syndromes, 2002, 31(1):27-37.
12. Wright TC, Jr., et al., 2001 consensus guidelines for the management of women with cervical cytological abnormalities, Journal of the American Medical Association, 2002, 287(16):2120-2129.
13. Kim JJ, Wright TC and Goldie SJ, Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance, Journal of the American Medical Association, 2002, 287(18):2382-2390.
14. Goldie SJ, Harvard School of Public Health, Boston, personal communication, Aug. 7, 2002.
15. Kulasingam SL and Myers ER, Department of Obstetrics and Gynecology, Duke University, Durham, NC, personal communication, Oct. 29, 2002; and Myers ER et al., Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis, American Journal of Epidemiology, 2000, 151(12):1158-1171.
16. National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) Program, SEER Cancer Statistics Review, 1973-1999, Table V-1, , accessed June 28, 2002.
17. Kim JJ, Wright TC and Goldie SJ, 2002, op. cit. (see reference 13); and Goldie SJ, 2002, op. cit. (see reference 14).
18. Kulasingam SL and Myers ER, 2002, op. cit. (see reference 15); and Myers ER et al., 2000, op. cit. (see reference 15).
19. Wiley DJ et al., External genital warts: diagnosis, treatment, and prevention, Clinical Infectious Diseases, 2002, 35(S2):S210-S224; and Centers for Disease Control and Prevention (CDC), 1993 sexually transmitted disease guidelines, Morbidity and Mortality Weekly Report, 1993, Vol. 42, No. RR-14, p. 83.
20. Richwald GA and Langley PC, Cost of care and treatment patterns for external genital warts (EGWs) in ob/gyn practices in the United States, International Journal of STD & AIDS, 2001, 12(S2):126; Beutner KR et al., External genital warts: report of the American Medical Association Consensus Conference, Clinical Infectious Diseases, 1998, 27(4):796-806; and Strauss MJ et al., The cost of treating genital warts, International Journal of Dermatology, 1996, 35(5):340-348.
21. Weinstock H, Berman S and Cates W, Jr., 2004, op. cit. (see reference 1); and Myers ER et al., 2000, op. cit. (see reference 15).
22. Weinstock H, Berman S and Cates W, Jr., 2004, op. cit. (see reference 1).
23. ASHA, 1998, op. cit. (see reference 2).
24. Weinstock H, Berman S and Cates W, Jr., 2004, op. cit. (see reference 1).
25. Tao G, Kassler WJ and Rein DB, Medical care expenditures for genital herpes in the United States, Sexually Transmitted Diseases, 2000, 27(1):32-38; Szucs TD et al., The estimated economic burden of genital herpes in the United States: an analysis using two costing approaches, BMC Infectious Diseases, 2001, Vol. 1, No. 5; and Armstrong GL et al., Incidence of herpes simplex virus type 2 infection in the United States, American Journal of Epidemiology, 2001, 153(9):912-920.
26. Fisman DN et al., Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States, Sexually Transmitted Diseases, 2002, 29(10):608-622.
27. Fisman DN, Drexel University School of Public Health, Philadelphia, personal communication, Dec. 9, 2002.
28. Fisman DN et al., 2002, op. cit. (see reference 26).
29. Margolis HS et al., Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations, Journal of the American Medical Association, 1995, 274(15):1201-1208.
30. Ibid.; and ASHA, 1998, op. cit. (see reference 2).
31. ASHA, 1998, op. cit. (see reference 2).
32. Shafer MAB, Pantell RH and Schachter J, Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Archives of Pediatrics & Adolescent Medicine, 1999, 153(2):119-125; Begley CE, McGill L and Smith PB, The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic, Sexually Transmitted Diseases, 1989, 16(2):63-67; Howell MR et al., Screening women for Chlamydia trachomatis in family planning clinics, Sexually Transmitted Diseases, 1998, 25(2):108-117; and Gift TL et al., The cost-effectiveness of jail-based STD and HIV prevention programs and their impact on inmate and community health, paper presented at the 2002 National STD Prevention Conference, San Diego, Mar. 4-7, 2002.
33. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); and Gift TL et al., 2002, op. cit. (see reference 32).
34. Begley CE, McGill L and Smith PB, 1989, op. cit. (see reference 32); and Howell MR et al., 1998, op. cit. (see reference 32).
35. CDC, Sexually transmitted diseases treatment guidelines 2002, Morbidity and Mortality Weekly Report, 2002, Vol. 51, No. RR-6.
36. Marrazzo JM et al., Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay, Annals of Internal Medicine, 1997, 127(9):796-803; Oh MK et al., Sexual behavior and sexually transmitted diseases among male adolescents in detention, Sexually Transmitted Diseases, 1994, 21(3):127-132; Oh MK et al., Urine-based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections, Archives of Pediatrics and Adolescent Medicine, 1998, 152(1):52-56; Turner CF et al., Untreated gonococcal and chlamydial infection in a probability sample of adults, Journal of the American Medical Association, 2002, 287(6):726-733; Farley TA, Cohen DA and Elkins W, Asymptomatic sexually transmitted diseases: the case for screening, Preventive Medicine, 2003; 36(4):502-509; and Mertz KJ et al., Findings from STD screening of adolescents and adults entering corrections facilities, Sexually Transmitted Diseases, 2002, 29(12):834-839.
37. CDC, 2002, op. cit. (see reference 35); and St. Lawrence JS et al., STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians, American Journal of Public Health, 2002, 92(11):1784-1788.
38. Marrazzo JM et al., Cost-effectiveness of urine-based screening for Chlamydia trachomatis with ligase chain reaction in asymptomatic males, poster presentation prepared for the annual meeting of the International Society for Sexually Transmitted Disease Research, Seville, Spain, Oct. 19-22, 1997; Washington AE, Johnson RE and Sanders LL, Jr., Chlamydia trachomatis infections in the United States: what are they costing us? Journal of the American Medical Association, 1987, 257(15):2070-2072; and Magid D, Douglas JM, Jr., and Schwartz JS, Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis, Annals of Internal Medicine, 1996, 124(4):389-399.
39. Marrazzo JM et al., 1997, op. cit. (see reference 38); Washington AE, Johnson RE and Sanders LL, Jr., 1987, op. cit. (see reference 38); Magid D, Douglas JM, Jr., and Schwartz JS, 1996, op. cit. (see reference 38); and Ginocchio RHS et al., The clinical and economic consequences of screening young men for genital chlamydial infection, Sexually Transmitted Diseases, 2003, 30(2):99-106. Morbidity and Mortality Weekly Report, 1993, Vol. 42, No. RR-12; Rees E, The treatment of pelvic inflammatory disease, American Journal of Obstetrics and Gynecology, 1980, 138(7, part 2):1042-1047; Douglas JM, Jr., et al., Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection, International Journal of STD & AIDS, 2001, 12(S2):65-67; Haddix AC, Hillis SD and Kassler WJ, The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women, Sexually Transmitted Diseases, 1995, 22(5):274-280; and Wiesenfeld HC et al., Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease, Obstetrics & Gynecology, 2002, 100(3):456-463.
40. Washington AE, Johnson RE and Sanders LL, Jr., 1987, op. cit. (see reference 38); Tait IA, Duthie SJ and Taylor-Robinson D, Silent upper genital tract chlamydia infection and disease in women, International Journal of STD & AIDS, 1997, 8(5):329-331; CDC, Recommendations for the prevention and management of Chlamydia trachomatis infections,
41. Douglas JM, Jr., et al., 2001, op. cit. (see reference 40); Haddix AC, Hillis SD and Kassler WJ, 1995, op. cit. (see reference 40); Hook EW 3rd et al., Use of cell culture and a rapid diagnostic assay for Chalmydia trachomatis screening, Journal of the American Medical Association, 1994, 272(11):867-870; and Bachmann L et al., Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center, Sexually Transmitted Diseases, 1999, 26(9):496-499.
42. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); Magid D, Douglas JM, Jr., and Schwartz JS, 1996, op. cit. (see reference 38); Yeh JM, Hook EW 3rd and Goldie SJ, A refined estimate of the average lifetime cost of pelvic inflammatory disease, Sexually Transmitted Diseases, 2003, 30(5):369-378; and Rein DB et al., Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial, Obstetrics & Gynecology, 2000, 95(3):397-402.
43. Rein DB et al., 2000, op. cit. (see reference 42).
44. Magid D, Douglas JM, Jr., and Schwartz JS, 1996, op. cit. (see reference 38); and Marrazzo JM et al., Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women, Sexually Transmitted Diseases, 1997, 24(3):131-141.
45. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); Begley CE, McGill L and Smith PB, 1989, op. cit. (see reference 32); and Gift TL et al., 2002, op. cit. (see reference 32).
46. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); and Gift TL et al., 2002, op. cit. (see reference 32).
47. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); and Begley CE, McGill L and Smith PB, 1989, op. cit. (see reference 32).
48. Ratelle S et al., Management of urethritis in health maintenance organization members receiving care at a multispecialty group practice in Massachusetts, Sexually Transmitted Diseases, 2001, 28(4):232-235.
49. Turner CF et al., 2002, op. cit. (see reference 36); Mertz KJ et al., 2002, op. cit. (see reference 36); Oh MK et al., Urine-based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections, Archives of Pediatrics & Adolescent Medicine, 1998, 152(1):52-56; and Farley TA, Cohen DA and Elkins W, 2003, op. cit. (see reference 36).
50. Marrazzo JM et al., 1997, op. cit. (see reference 38); Washington AE, Johnson RE and Sanders LL, Jr., 1987, op. cit. (see reference 38); and Ginocchio RHS et al., 2003, op. cit. (see reference 39).
51. Washington AE, Johnson RE and Sanders LL, Jr., 1987, op. cit. (see reference 38); Tait IA, Duthie SJ and Taylor-Robinson D, 1997, op. cit. (see reference 40); Rees E, 1980, op. cit. (see reference 40); Douglas JM, Jr., et al., 2001, op. cit. (see reference 40); Haddix AC, Hillis SD and Kassler WJ, 1995, op. cit. (see reference 40); Wiesenfeld HC et al., 2002, op. cit. (see reference 40); Westrom L and Eschenbach D, Pelvic inflammatory disease, in: Holmes KK et al., eds., Sexually Transmitted Diseases, New York: McGraw-Hill, 1999, pp. 783-809; and Gutman LT, Gonococcal diseases in infants and children, in: ibid., pp. 1145-1154.
52. Douglas JM, Jr., et al., 2001, op. cit. (see reference 40).
53. Ibid.; and Haddix AC, Hillis SD and Kassler WJ, 1995, op. cit. (see reference 40).
54. St. Lawrence JS et al., 2002, op. cit. (see reference 37); and Farley TA, Cohen DA and Elkins W, 2003, op. cit. (see reference 36).
55. Shafer MAB, Pantell RH and Schachter J, 1999, op. cit. (see reference 32); Begley CE, McGill L and Smith PB, 1989, op. cit. (see reference 32); Howell MR et al., 1998, op. cit. (see reference 32); and Gift TL et al., 2002, op. cit. (see reference 32).
56. Krieger JN and Alderete JF, Trichomonas vaginalis and trichomoniasis, in: Holmes KK et al., 1999, op. cit. (see reference 51), pp. 587-604; and Bowden FJ and Garnett GP, Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions, Sexually Transmitted Infections, 2000, 76(4):248-256.
57. Chesson HW et al., Direct medical costs of syphilis in the United States: the potential for a cost-saving national elimination program, paper presented at the 1998 National STD Prevention Conference, Dallas, Dec. 6-9, 1998.
58. Ibid.; Division of STD Prevention, CDC, Sexually Transmitted Disease Surveillance, 2000, Atlanta: CDC, 2001; and Kraut JR et al., Cost-effectiveness of routine screening for sexually transmitted diseases among inmates in United States prisons and jails, in: National Commission on Correctional Health Care (NCCHC), The Health Status of Soon-to-Be-Released Inmates: A Report to Congress, Chicago: NCCHC, 2002, pp. 81-108.
59. Kraut JR et al., 2002, op. cit. (see reference 58); and Sparling PF, Natural history of syphilis, in: Holmes KK et al., 1999, op. cit. (see reference 51), pp. 473-478.
60. Kinosian BP et al., Predicting 10-year care requirements for older people with suspected Alzheimer's disease, Journal of the American Geriatrics Society, 2000, 48(6):631-638.
61. Chesson HW et al., 1998, op. cit. (see reference 57).
62. Kraut JR et al., 2002, op. cit. (see reference 58); and Silberstein GS et al., Effectiveness and cost-benefit of enhancements to a syphilis screening and treatment program at a county jail, Sexually Transmitted Diseases, 2000, 27(9):508-517.
63. Kahn JG et al., Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men, Journal of Acquired Immune Deficiency Syndromes, 2001, 27(5):482-491; Pinkerton SD, Holtgrave DR and Jemmott JB 3rd, Economic evaluation of HIV risk reduction intervention in African-American male adolescents, Journal of Acquired Immune Deficiency Syndromes, 2000, 25(2):164-172; Tao G and Remafedi G, Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1998, 17(1):83-90; Wang LY et al., Economic evaluation of Safer Choices: a school-based human immunodeficiency virus, other sexually transmitted diseases, and pregnancy prevention program, Archives of Pediatrics & Adolescent Medicine, 2000, 154(10):1017-1024; and Wang LY, Burstein GR and Cohen DA, An economic evaluation of a school-based sexually transmitted disease screening program, Sexually Transmitted Diseases, 2002, 29(12):737-745.
64. Wasserheit JN, Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases, Sexually Transmitted Diseases, 1992, 19(2):61-77; and Chesson HW and Pinkerton SD, Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions, Journal of Acquired Immune Deficiency Syndromes, 2000, 24(1):48-56.
65. Chesson HW and Pinkerton SD, 2000, op. cit. (see reference 64).
66. Bozzette SA et al., 2001, op. cit. (see reference 10).
67. CDC, 2002, op. cit. (see reference 35); and Saslow D et al., American Cancer Society guideline for the early detection of cervical neoplasia and cancer, CA: A Cancer Journal for Clinicians, 2002, 52(6):342-362.